Introduction {#s1}
============

The growing global cancer burden has accelerated the innovation in treatment, including the influx of new drugs. Nevertheless, skyrocketing healthcare costs, especially for antineoplastic agents combined with modest survival gains, raise questions that new anticancer drugs are not necessarily cost-effective ([@B9]; [@B18]; [@B5]).

Value, a relatively new, emerging and evolving term, which has eight separate but distinct definitions according to the *Oxford English Dictionary* ([@B13]), is recognized as a multidimensional and dynamic concept with consensus, despite the fact that its definition may vary among different stakeholders, including physicians, payers, patients, *etc*. ([@B14]).

With promoting the use of high-value drugs, a number of organizations, including the American Society of Clinical Oncology (ASCO) ([@B15]; [@B16]), European Society for Medical Oncology (ESMO) ([@B3]; [@B4]), and National Comprehensive Cancer Network (NCCN) ([@B12]) have developed frameworks to assess antineoplastic agents either quantitatively or qualitatively, involving stakeholders (e.g., physicians, patients, and healthcare insurers). However, there is no a universally accepted framework and unfortunately no value assessment frameworks in developing countries, e.g. China, with scarce resources and rising demand for healthcare services.

Off-label use for antineoplastic agents, sometimes the only option for patients with advanced cancer in real-world settings, is an inevitable challenge and remains to be solved urgently in clinical practice. However, at present, lack of general specification and technical criteria for evaluation is tangible. Similar with "new drugs" or "new treatment" compared with a standard therapeutic regimen, it is feasible to use a value assessment framework to comprehensively evaluate off-label use for antineoplastic agents, so as to solve the technical bottleneck for evaluation of off-label use of antineoplastic agents.

Although there are compendiums of indicators for value assessment, there are currently no validated indicators to guide implementation and value evaluation of off-label use of antineoplastic agents. The aim of the present study was to explore establishment of the first value assessment index system for off-label use of antineoplastic agents in China using the modified Delphi method, which encompassed an iterative process and has been widely applied in diverse areas of healthcare system.

Methods {#s2}
=======

To develop a value assessment index system for off-label use of antineoplastic agents in China, a modified Delphi method was employed to establish consensus within a ﬁeld to reach agreement *via* a questionnaire or doing interview among a multidisciplinary panel of experts by collecting their feedback to inform the next round, exchanging their individual knowledge, experience and opinions anonymously, and resolving uncertainties ([@B6]). Until consensus was reached on the final round, an agreement was identified ([@B7]; [@B2]). The flowchart of the Delphi process is shown in [**Figure 1**](#f1){ref-type="fig"}, and detailed description of the proposed system is presented in Appendix.

![Study design of the Delphi method.](fphar-11-00771-g001){#f1}

Results {#s3}
=======

Totally, two rounds of consultation were carried out, and then, the consensus was reached.

Characteristics of the Experts {#s3_1}
------------------------------

A multidisciplinary panel enrolled 19 participants for consultation from geographically diverse areas, including North, South, and West of China who met experts' defined criteria. Eighteen experts agreed to participate in the first and second rounds. All the experts had at least nine or more years of experience (range of experience, 9--29 years; mean, 18.2 years). Experts were predominantly (*n* = 17) working in hospitals and were employed in clinical pharmacy, pharmaceutical affairs, oncology, evidence-based medicine, clinical epidemiology and statistics, or pharmacoeconomics. Demographic characteristics of participants, including gender, profession, the highest level of education, etc. were also collected and shown in [**Table 1**](#T1){ref-type="table"}.

###### 

Characteristics of expert panelists.

  Categories                           Characteristics     Number   Percentage (%)
  ------------------------------------ ------------------- -------- ----------------
  Response to questionnaires           Round 1             18       94.7
  Round 2                              18                  100      
  Gender                               Male                12       66.7
  Female                               6                   33.3     
  Educational attainment               Doctor's degree     7        38.9
  Master's degree                      9                   50       
  Bachelor's degree                    2                   11.1     
  Organization                         Hospital            17       94.4
  Academic organization                1                   5.6      
  Types of expertise                   oncologists         4        22.2
  pharmacists                          4                   22.2     
  Pharmacy director                    5                   27.8     
  Policy makers                        5                   27.8     
  Main research areas                  Clinical pharmacy   5        27.8
  Pharmaceutical affairs               5                   27.8     
  Oncology                             4                   22.2     
  Evidence-based medicine              2                   11.1     
  Clinical epidemiology & statistics   1                   5.6      
  Pharmacoeconomics                    1                   5.6      
  Professional title                   Senior              6        33.3
  Associate senior                     12                  66.7     
  Professional years                   20\~                6        33.3
  10--20                               10                  55.6     
  \<10                                 2                   11.1     
  Province or region                   Sichuan             12       66.7
  Chongqing                            1                   5.6      
  Liaoning                             1                   5.6      
  Guangdong                            4                   22.2     
  Familiarity degree                   Very Familiar       2        11.1
  A little familiar                    13                  72.2     
  Familiar commonly                    3                   16.7     

Expert's Positive Coefficient {#s3_2}
-----------------------------

In general, expert positive coefficient (*C~aj~*) was 94.74% in the first round and 100.00% in the second round.

Expert's Authority Coefficient {#s3_3}
------------------------------

In the first round, expert's authority coefficient (*C~r~*) for majority of 61 indicators was ≥ 0.80 (85.2%, ranging from 0.70 to 0.89, mean=0.84), and coefﬁcient of variation (*CV*) for all the 61 indicators was ≥ 22% (ranging from 11.67% to 21.74%, mean=17.4%). After two rounds, *C~r~* for the majority of indicators was higher than that of the first round. The average *C~r~* raised to 0.85 (ranging from 0.75 to 0.90), and *CV* for all the indicators was \< 20% (ranging from 10.49% to 19.71%, mean=15.97%), indicating that consensus has been achieved.

[**Table 2**](#T2){ref-type="table"} compares values of *C~r~* between the first round and the second round.

###### 

Comparison of expert authority degree with two Delphi rounds.

  Round one                                                                                        Round two   Round one expert authority coefficient   Round one expert authority coefficient          
  ------------------------------------------------------------------------------------------------ ----------- ---------------------------------------- ---------------------------------------- ------ -------
  Labor impairment extent                                                                          Reserve     0.83                                     18.14                                    0.85   10.61
  Personal psychological burden                                                                    Reserve     0.81                                     16.6                                     0.81   13.29
  Social activities extent                                                                         Reserve     0.76                                     19.9                                     0.75   16.19
  Proportion of family expenses for illness                                                        Reserve     0.84                                     15.24                                    0.84   12.69
  Family members' psychological burden                                                             Reserve     0.79                                     17.66                                    0.81   14.43
  Personal productivity affection on socio-economic                                                Reserve     0.77                                     18.4                                     0.79   13.67
  Government image                                                                                 Delete      0.73                                     19.4                                     --     --
  popular psychology                                                                               Delete      0.7                                      20.93                                    --     --
  Social stability                                                                                 Delete      0.71                                     19.34                                    --     --
  The necessity of off-label use for drugs                                                         Reserve     0.89                                     11.67                                    0.88   11.81
  Standard regimen available as control                                                            Reserve     0.88                                     12.94                                    0.88   11.32
  Hazard Ratio                                                                                     Reserve     0.85                                     17.47                                    0.85   13.53
  Overall survival rate                                                                            Reserve     0.86                                     17.54                                    0.87   12.8
  Overall survival                                                                                 Reserve     0.87                                     15.55                                    0.89   10.66
  Progression-free survival rate                                                                   Reserve     0.87                                     17.02                                    0.87   13.51
  Progression-free survival                                                                        Reserve     0.85                                     17.93                                    0.86   15.12
  Overall response rate                                                                            Reserve     0.85                                     17.7                                     0.88   14.65
  Adverse reaction grading                                                                         Reserve     0.89                                     12.65                                    0.9    10.49
  Adverse reaction incidence                                                                       Reserve     0.89                                     12.35                                    0.9    10.78
  Duration of adverse reactions                                                                    Reserve     0.88                                     13.65                                    0.88   12.39
  Treatment-free interval                                                                          Reserve     0.81                                     19.17                                    0.82   18.26
  Quality of life                                                                                  Reserve     0.88                                     14.33                                    0.89   11.74
  Symptoms remission with patients reported                                                        Reserve     0.83                                     18.94                                    0.85   16.15
  Treatment cost per course                                                                        Reserve     0.88                                     13.79                                    0.89   11.8
  Proportion of patients' out-of-pocket expenses (total course)                                    Reserve     0.87                                     13.83                                    0.88   12.28
  Other forms of cost compensation                                                                 Reserve     0.8                                      21.74                                    0.77   25.31
  Expenses proportion to develop and deploy new drugs                                              Delete      0.77                                     20.26                                    --     --
  Development cycle for new drugs                                                                  Delete      0.77                                     20.69                                    --     --
  Innovation international                                                                         Reserve     0.8                                      18.32                                    0.83   18.67
  Innovation in China                                                                              Reserve     0.8                                      18.32                                    0.83   18.83
  Affordable access for drugs (generic drugs or quality consistency evaluation of generic drugs)   Reserve     0.86                                     17.8                                     0.88   17.28
  Therapeutic regimen alternative                                                                  Reserve     0.83                                     19.63                                    0.85   19.44
  Clinical practice guideline                                                                      Reserve     0.88                                     18.52                                    0.88   18.18
  Cochrane systematic review                                                                       Reserve     0.86                                     20.52                                    0.88   17.56
  Other systematic reviews (including meta-analysis)                                               Reserve     0.86                                     18.53                                    0.86   18.69
  Randomized controlled trial (phase III)                                                          Reserve     0.89                                     18.76                                    0.88   19.1
  Randomized controlled trial (phase II)                                                           Reserve     0.87                                     17.94                                    0.86   18.77
  Cohort study                                                                                     Reserve     0.85                                     18.05                                    0.84   17.1
  Case-control study                                                                               Reserve     0.83                                     18.86                                    0.83   17.97
  Case series                                                                                      Reserve     0.84                                     17.68                                    0.83   16.67
  Case report                                                                                      Reserve     0.86                                     17.11                                    0.85   16.75
  Expert consensus                                                                                 Reserve     0.87                                     16.12                                    0.87   16.08
  Multidisciplinary collaboration                                                                  Reserve     0.87                                     15.55                                    0.86   16.37
  Evidence submitted by pharmaceutical manufacturers                                               Reserve     0.84                                     16.71                                    0.82   16.76
  Evidence recommendation                                                                          Reserve     0.86                                     18.71                                    0.87   18.56
  Quality grading of evidence                                                                      Reserve     0.86                                     19.26                                    0.86   19.6
  Validity                                                                                         Reserve     0.85                                     17.24                                    0.86   17.54
  Applicability                                                                                    Reserve     0.85                                     18.16                                    0.85   19.02
  Clinical importance                                                                              Reserve     0.86                                     17.62                                    0.87   17.36
  Consistent results reported from at least two same type of study as evidence                     Reserve     0.84                                     18.21                                    0.84   18.14
  Single report as evidence                                                                        Reserve     0.83                                     19.08                                    0.83   18.27
  New types of evidence                                                                            Reserve     0.84                                     17.74                                    0.82   17.85
  Evidence updated                                                                                 Reserve     0.85                                     18.05                                    0.84   18.59
  Weight for indicators                                                                            Reserve     0.83                                     19.24                                    0.83   19.71
  Weight for evidence type                                                                         Reserve     0.82                                     19.65                                    0.81   19.29
  Weight for evidence grading                                                                      Reserve     0.81                                     19.52                                    0.83   16.85
  Synthesis of evidence results                                                                    Reserve     0.79                                     16.59                                    0.78   14.99
  Issued by association                                                                            Reserve     0.84                                     15.68                                    0.86   16.02
  Issued by hospitals and its alliance                                                             Reserve     0.85                                     13.26                                    0.86   13.73
  Issued regularly                                                                                 Reserve     0.86                                     16.15                                    0.85   16.14
  Issued irregularly, as evidence updated                                                          Reserve     0.86                                     14.72                                    0.85   15.23

Degree of Coordination of Experts' Opinions {#s3_4}
-------------------------------------------

*P*-values of Kendall's *W* test were all \< 0.001 for each round. At the end of the second round, *W*-value for concordance of final indicators was 0.395 (χ^2^=347.494, *P*\<0.0001), which was statistically significant at the level of *α*=0.05, indicating that the consensus could be reached among the experts ([**Table 3**](#T3){ref-type="table"}).

###### 

Result of expert opinion coordination degree.

  Rounds       Round one   Round two                             
  ------------ ----------- ----------- ------- ------- --------- -------
  Domains      0.323       40.663      0.000   0.487   61.312    0.000
  Subdomains   0.272       92.459      0.000   0.374   127.314   0.000
  Indicators   0.310       289.800     0.000   0.395   347.495   0.000

A Value Assessment Framework for Off-Label Use of Antineoplastic Agents {#s3_5}
-----------------------------------------------------------------------

During the first round, the experts were invited to rate their opinions on 61 candidate indicators identified in the questionnaire. The second round was held to discuss answers from the ﬁrst round's survey. After two rounds, a consensus of deleting five indicators, refining the expression of one indicator, and compressing indicators into three levels was achieved. Changes of indicators in two rounds were summarized in [**Table 4**](#T4){ref-type="table"}.

###### 

Indicator changes in two Delphi rounds.

  Original indicators                           Modified results
  --------------------------------------------- -----------------------------
  Investment in drug research and development   Delete
  Popular psychology                            Delete
  Government Image                              Delete
  Social stability                              Delete
  Cost ratio on research and development        Delete
  Research and development cycle                Delete
  Risk factors                                  Modified to: adverse effect

Consequently, after two rounds of consultation with experts, we generated an expert consensus around the final value assessment index system for off-label use of antineoplastic agents that was comprised of eight domains, 21 subdomains, and 56 indicators ([**Table 5**](#T5){ref-type="table"}).

###### 

Value assessment index system.

  Domains                                                         Subdomains                                                                                       Indicators                                                                     Combination weight
  --------------------------------------------------------------- ------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------ --------------------
  Disease burden                                                  Individual burden                                                                                Abor impairment extent                                                         0.85
  Personal psychological burden                                   0.78                                                                                                                                                                            
  Social activities extent                                        0.66                                                                                                                                                                            
  Family burden                                                   Proportion of family expenses for illness                                                        1.08                                                                           
  Family members' psychological burden                            0.88                                                                                                                                                                            
  Social burden                                                   Personal productivity affection on socio-economic                                                1.36                                                                           
  Therapeutic value                                               Benefit value                                                                                    The necessity of off-label use for drugs                                       1.43
  Standard regimen available as control                           1.54                                                                                                                                                                            
  Hazard ratio                                                    1.45                                                                                                                                                                            
  Overall survival rate                                           1.50                                                                                                                                                                            
  Overall survival                                                1.50                                                                                                                                                                            
  Progression-free survival rate                                  1.51                                                                                                                                                                            
  Progression-free survival                                       1.49                                                                                                                                                                            
  overall response rate                                           1.51                                                                                                                                                                            
  Adverse reaction                                                Adverse reaction grading                                                                         3.58                                                                           
  Adverse reaction incidence                                      3.33                                                                                                                                                                            
  Duration of adverse reactions                                   3.14                                                                                                                                                                            
  Survival value                                                  Treatment-free interval                                                                          4.44                                                                           
  Quality of life                                                 4.44                                                                                                                                                                            
  Symptoms remission with patients reported                       4.22                                                                                                                                                                            
  Economic affection                                              Treatment cost per course                                                                        2.56                                                                           
  Proportion of patients' out-of-pocket expenses (total course)   2.59                                                                                                                                                                            
  Other forms of cost compensation                                1.88                                                                                                                                                                            
  Drug novelty                                                    Innovation value                                                                                 Innovation international                                                       2.18
  Innovation in China                                             2.14                                                                                                                                                                            
  Alternative                                                     Affordable access for drugs (generic drugs or quality consistency evaluation of generic drugs)   2.27                                                                           
  Therapeutic regimen alternative                                 2.35                                                                                                                                                                            
  evidence source and type                                        Secondary studies                                                                                Clinical practice guideline                                                    2.05
  Cochrane systematic review                                      1.95                                                                                                                                                                            
  Other systematic reviews (including Meta-analysis)              1.78                                                                                                                                                                            
  Clinical trials                                                 Randomized controlled trial (phase III)                                                          3.51                                                                           
  Randomized controlled trial (phase II)                          3.53                                                                                                                                                                            
  Real world research                                             Cohort study                                                                                     0.80                                                                           
  Case-control study                                              0.79                                                                                                                                                                            
  Case series                                                     0.74                                                                                                                                                                            
  Case report                                                     0.71                                                                                                                                                                            
  others                                                          Expert consensus                                                                                 0.33                                                                           
  Multidisciplinary collaboration                                 0.32                                                                                                                                                                            
  Evidence submitted by pharmaceutical manufacturers              0.28                                                                                                                                                                            
  Grading of evidence recommendation                              Evidence evaluation methods/tools                                                                Evidence recommendation                                                        1.72
  Quality grading of evidence                                     1.71                                                                                                                                                                            
  Evidence evaluation objective                                   Validity                                                                                         1.12                                                                           
  Applicability                                                   1.12                                                                                                                                                                            
  Clinical importance                                             1.21                                                                                                                                                                            
  Consistency of evidence results                                 Consistency                                                                                      Consistent results reported from at least two same type of study as evidence   1.52
  Single report as evidence                                       1.37                                                                                                                                                                            
  Update/correction                                               New types of evidence                                                                            1.47                                                                           
  Evidence updated                                                1.42                                                                                                                                                                            
  Value composition/integration                                   Weight of results                                                                                Weight for indicators                                                          0.70
  Weight for evidence type                                        0.65                                                                                                                                                                            
  Weight for evidence grading                                     0.68                                                                                                                                                                            
  Results forms                                                   Synthesis of evidence results                                                                    2.25                                                                           
  Public feedback/comments                                        Public feedback mechanism                                                                        Issued by association                                                          2.84
  Issued by hospitals and its alliance                            2.53                                                                                                                                                                            
  Frequency of public feedback                                    Issued regularly                                                                                 2.16                                                                           
  Issued irregularly, as evidence updated                         2.08                                                                                                                                                                            

Discussion {#s4}
==========

Main Findings {#s4_1}
-------------

To our knowledge, this is the first Delphi-based study performed among a diverse panel of experts to develop a value assessment index system for off-label use of antineoplastic agents in China with eight domains, 21 subdomains, and 56 well-defined indicators at the end of two rounds. We believe that our study has filled an important gap on value assessment for off-label use of antineoplastic agents to address the difficulties in knowledge and practice in developing countries (e.g., China).

Although our framework was developed in the Chinese context, we believe that it can be implemented in other countries for assessing adherence to best decision-making, practice, and management in off-label use of antineoplastic agents.

Strengths and Limitations {#s4_2}
-------------------------

Our study has several strengths. Firstly, the eight domains in the framework, which were strongly endorsed by the experts, disease burden, and novelty in drug discovery, covered different types of cancer burden about the state, society, and individual, and also reflected the orientation of drug research and development policy in China. Source and type of evidence, grading of evidence recommendation, and consistency of evidence-based results highly condensed the methodological support of evidence-based medicine for the present study, and emphasized the importance of evidence and patients' decision-making. These key domains were not proposed in other value assessment frameworks, and they therefore can be used in global scale.

Secondly, we invited 18 well-known experts in related fields who concentrated on clinical pharmacy, pharmaceutical affairs, oncology, evidence-based medicine, clinical epidemiology and statistics, and pharmacoeconomics, 16 of which had doctor's or master's degrees. The number of experts should be appropriately selected for a Delphi-based study ([@B7]). Expert's positive coefficient was 94.74% in the first round, while that was 100.00% in the second round, indicating that experts were interested in this research, and were willing to fill out the survey within the specified timeframe. The mean expert's authority coefficient was 0.84 and that was ≥ 0.80 for the majority of 61 indicators in the first round, and then, raised to 0.85 in the second round, indicating a high degree of experts' authority in the field of value evaluation of off-label use of antineoplastic agents in the Delphi surveys and qualifying them for participation in the survey.

Thirdly, a reasonable weight setting is crucial for establishing an index system. In the present study, therapeutic value plays a leading role in value assessment index system, demonstrating that multiple forms of evidence should be taken into account for value assessment, including but not limited to patient-reported outcomes, results from randomized controlled trials(RCTs), and real-world evidence as appropriate. The weight coefficient of the first-level indicators was in the following order: therapeutic value (0.4211), source and type of evidence (0.1678), public feedback/comments (0.0961), novelty in drug discovery (0.0894), grading of evidence recommendation (0.0689), consistency of evidence-based results (0.0578), disease burden (0.0561), and ratio of composition/integration (0.0428). Obviously, the top three weights were therapeutic value, source and type of evidence, and public feedback/comments, which highly condensed the methodological support of evidence-based medicine for the current study and emphasized the importance of evidence and patients' decision-making ([@B20]).

Fourthly, open questions were raised during each round to gain more in-depth insight into the indicator, promoting more well-defined indicators, as well as ensuing guidance for satisfactory practice, so that the index system could be more appropriate for the purpose of value assessment.

However, the present study has also a number of limitations. Firstly, we did not include potential experts from some provinces or regions across China (i.e., east of China, which could limit our results). Secondly, we did not include payers of healthcare for consultation, which are important stakeholders in the value assessment of pharmacotherapy. Thirdly, the present study did not provide a face-to-face meeting for experts to discuss disagreement. Fourthly, Delphi consensus has its own limited validity. Fifthly, there were a great number of indicators, and it is therefore necessary to remove those indicators with low operability in the future according to empirical research on different types of cancer and drugs.

Future research should aim at setting an international consensus on a value assessment index system for off-label use of antineoplastic agents using Delphi method as a contribution to robust evidence for governments' evidence-based decision-making, providing further insights into value and its relevance with drug prices to promote value-oriented medicine.

Conclusions {#s5}
===========

We conducted a Delphi-based method and process to develop and validate the first value assessment index system for off-label use of antineoplastic agents in China. The ﬁnal 56 indicators need to be further tested, veriﬁed, and revised in clinical practice.

Appendix {#s6}
========

Producing an Evidence-Based Candidate Indicators List {#s6_1}
-----------------------------------------------------

According to the comprehensive overview of global value assessment tools for drugs, a total of 12 eligible value assessment tools for drugs were identiﬁed ([@B8]). They covered basic characteristics, key elements, and techniques in terms of value domains and metrics, evidence source/grading, development process, in which a detailed value assessment index system was presented and grouped into three levels, including eight domains, 22 subdomains, and 61 indicators. The eight domains were as follows: *i*) disease burden, *ii*) therapeutic value, *iii*) novelty in drug discovery, *i*v) source and type of evidence, *v*) grading of evidence recommendation, *vi*) consistency of evidence-based results, *vii*) ratio of composition/integration, and *viii*) public feedback/comments ([**Figure 2**](#f2){ref-type="fig"}).

![Conceptual framework of value assessment.](fphar-11-00771-g002){#f2}

Recruitment of Experts in a Multidisciplinary Panel {#s6_2}
---------------------------------------------------

A purposive, criterion-based sampling approach was adopted to convene a multidisciplinary panel of experts, providing detailed explanation and objectives for our study to promote the acceptance of the final index system. With random sampling of mathematical statistics theory, the relationship between the mean sample standard deviation *σ* and the population standard deviation $\overline{\sigma}$ can be formulated as follows:

σ

¯

=

σ

m

where, *m* represents the number of experts, and *m* increases, while $\overline{\sigma}$ decreases. Typically, a panel of 4\~16 experts can bring out satisfying results, while for those relatively important issues, such as indicator design or weight distribution, 15\~30 experts need to be considered to create diversity regarding representation ([@B1]; [@B17]). Delphi does not use random sampling to recruit a panel of experts, in contrast to conventional surveys, which generally hold an aim of representativeness ([@B19]; [@B10]).

Materials and Consultation {#s6_3}
--------------------------

Each round of questionnaire was delivered initially *via* e-mail and later by telephone. Experts were questioned about the importance, operability, and sensitivity, and then, ranked each indicator on a Likert-type scale ([@B1]) from 1-point (extremely inappropriate) to 5-point (extremely appropriate). Meanwhile, familiarity and judgment scores were recorded. Familiarity was divided into a Likert-type scale ([@B10]) where 1-point indicated that the expert is highly unfamiliar with the indicator and 5-point denoted that the expert is highly familiar with the indicator. Judgment criteria included four aspects: work experience, theoretical analysis, understanding from domestic and foreign counterparts, and intuition demonstrating the degree of influence, with scores of 1\~3 points ([**Supplementary Tables 1**](#SM1){ref-type="supplementary-material"} and [**2**](#SM1){ref-type="supplementary-material"}). Besides, open questions through each round were allowed, so as to encourage experts to revise, delete or add indicators, which they perceived to be necessary for the index system prior to the following survey round. The indicators were adjusted and supplemented according to the experts' comments. Then, the questionnaire was modified following the qualitative feedback and statistical analysis from the last round to the next. The final consultation with consensus achieved could lead to the final index system.

There is little evidence on the optimal number of Delphi rounds. Consensus is expected to increase with each additional round. However, potential bias also increases with experts' fatigue or attrition. Therefore, mean scores ≥ 0.70 and *CV* ≤ 25% were set as the consensus level in the present study ([@B11]).

Statistical Analysis {#s6_4}
--------------------

The expert consultation database was established through Epi Data (version 3.1), exported into Excel 2016 spreadsheets, and all statistical analyses were carried out by SPSS 25.0 software (IBM, Armonk, NY, USA). Both descriptive statistics and quantitative analyses were undertaken. Each round of the Delphi survey was analyzed separately. A two-tailed *P*-value \< 0.05 was considered statistically signiﬁcant. Descriptive information about experts' gender, level of education, professional title, *etc*. was recorded.

The mean scores and *CV* were calculated for each indicator and round. *CV* ≤ 25% indicated less variability of the experts' opinions.

Expert's positivity coefficient (*C~aj~*) and expert's authority coefficient (*C~r~*), involving two factors (the judgment criteria for the indicators (*C~a~*) and the experts' familiarity with the indicators (*C~s~*)), were correlated together as follows: *C~r~*=(*C~a~*+*C~s~*)/2. *P*-values of Kendall's *W* test and *W*-values were determined to evaluate the expert's positive degree, expert's authority degree, and degree of coordination of experts' opinions ([@B10]). Mean scores ≥ 0.70 and *CV* ≤ 25% were recommended for Delphi studies and set as the consensus level ([@B19]), and results that failed to meet either of the above-mentioned criteria indicated that no consensus could be achieved.
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